EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes

Tiffany Li, Terry Trinh, Annmarie Bosco, Matthew C Kiernan, David Goldstein, Susanna B Park

Supportive Care in Cancer · 2024

DOI: 10.1007/s00520-024-08484-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Tiffany Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Mind Centre, The University of Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Hematologic Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Institute NSW, National Health and Medical Research Council, National Health and Medical Research Council, Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Decades following the introduction of vincristine as treatment for haematological malignancies, vincristine-induced peripheral neuropathy (VIPN) remains a pervasive, untreatable side-effect. However there remains a gap in understanding the characteristics of VIPN in adults. This study presents a comprehensive phenotyping of VIPN.

Methods

Adult patients ( n = 57; age = 59.8 ± 14.6) were assessed cross-sectionally following completion of vincristine (months post treatment = 16.3 ± 15.6, cumulative dose = 7.6 ± 4.4), with a subset of 20 patients assessed prospectively during treatment. Patient reported measures (EORTC-QLQ-CIPN20, R-ODS) were used to profile symptoms and disability. Neurological assessment was undertaken using the Total Neuropathy Score and nerve conduction studies. Sensory threshold and fine motor tasks were also undertaken. Comparisons of data between timepoints were calculated using paired-sample t tests or Wilcoxon matched-pairs signed-rank test. Comparisons between outcome measures were calculated with independent sample t tests or Mann–Whitney U tests for non-parametric data.

Results

The majority of patients developed VIPN by mid-treatment (77.8%, 7.0 ± 3.3 weeks post baseline) with the prevalence remaining stable by end-of-treatment (75%, 8.1 ± 1.7 weeks post mid-treatment). By 3 months post-completion, 50% of patients still reported VIPN although there were significant improvements on neurological grading and functional assessment ( P < 0.05). VIPN presented with sensorimotor involvement in upper and lower limbs and was associated with decreased sensory and motor nerve amplitudes, reduced fine-motor function and increased disability.

Conclusion

VIPN in adults presents as a sensorimotor, upper- and lower-limb neuropathy that significantly impacts disability and function. Neuropathy recovery occurs in a proportion of patients; however, VIPN symptoms may persist and continue to affect long-term quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Nervous System DiseasesHematologic NeoplasmsAdultHumansMiddle AgedAgedQuality of LifeVincristineLower Extremity

Stichwörter der Autor:innen

Natural historyNerve conductionPatient reported outcomesPhenotypeVincristine-induced peripheral neuropathy

Substanzen

Vincristine

Autor:innen und Institutionen

  • Brain and Mind Centre, The University of Sydney, Sydney, Australia.
  • School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, 94 Mallett St Camperdown, Sydney, NSW, 2050, Australia.
  • Prince of Wales Clinical School, University of New South Wales, Kensington, Australia.
  • Prince of Wales Hospital, Randwick, Australia.
  • Department of Neurology, Royal Prince Alfred Hospital, Sydney, Australia.
  • Brain and Mind Centre, The University of Sydney, Sydney, Australia. Susanna.park@sydney.edu.au.

Förderung

  • Cancer Institute NSW
  • National Health and Medical Research Council
  • National Health and Medical Research Council, Australia
  • Cancer Institute NSW Program Grant
  • University of Sydney

Zitieren

APA

Li, T., Trinh, T., Bosco, A., Kiernan, M. C., Goldstein, D., & Park, S. B. (2024). Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08484-5

Vancouver

Li T, Trinh T, Bosco A, Kiernan MC, Goldstein D, Park SB. Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08484-5

BibTeX
@article{Li2024,
  author = {Li, Tiffany and Trinh, Terry and Bosco, Annmarie and Kiernan, Matthew C and Goldstein, David and Park, Susanna B},
  title = {Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes},
  journal = {Supportive Care in Cancer},
  year = {2024},
  doi = {10.1007/s00520-024-08484-5}
}
Kostenlos starten →